AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04426474
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT04269954
Drug: Batroxobin combined with low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment of Batroxobin combined with low molecular weight heparin
Trial: NCT05586750
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 x 20mg placebo (daily), taken orally. Identical appearance to study drug
Trial: NCT00811837
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous infusion
Trial: NCT01939145
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (0.9% NaCl) is an isotonic solution that is widely used for intravenous application but is also used as our SOC for wound irrigation. This solution has high tolerability. Normal saline has been used as the instillation solution for NPWTi. The dwell setting for this solution is 20 minutes. The volume of solution to be used is dependent on the size of the wound hence varies
Trial: NCT02020161
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00000621
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02740985
Drug: AZD4635
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD4635 will be administered orally as a nanosuspension or capsule on a continuous schedule in Arms A, B, C, D, E, F, G, H, I, J, K, KD, L, AA, and EA. The AZD4635 nanoparticle drug product will be constituted extemporaneously as an oral suspension by the patient immediately prior to dosing. In Arms CA, CB, and CC AZD4635 will be administered as 75 mg or 50 mg capsules. Additionally, in Arm CA, AZD4635 will also be administered at 150 mg and 200 mg, or a lower dose of 125 mg or 100 mg may be given.
Trial: NCT04736355
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral, for 24 weeks
Trial: NCT03713801
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets titrated up to 3 tablets over the course of 3 weeks and then continued as 3 daily for a total exposure of 12 weeks
Trial: NCT00867607
Drug: Steroid
RxNorm normalized name: Steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: b.i.d. 21 days
Trial: NCT00586157
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo skin patch titrated to 20mg (at 10 mg and 20 mg doses)
Trial: NCT00145730
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01318681
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a placebo nasal spray and placebo capsule are available for double dummy treatment
Trial: NCT02573064
Drug: Tigecycline
RxNorm normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00693758
Drug: adenosine
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intravenous infusion of adenosine (140microgr./min/kg)
Trial: NCT01846026
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02229617
Drug: Subcutaneous testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01270152
Drug: Ascorbic Acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: comparing three different doses of ascorbic acid: 50 mg, 100 mg and 200 mg administered inside the catheter and maintained for up to 60 minutes
Trial: NCT00470522
Drug: Methotrexate and folic acid
RxNorm normalized name: ferrous fumarate and folic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02150161
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02972645
Drug: LY3305677
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT02972645
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT00664222
Drug: spironolactone + furosemide
RxNorm normalized name: furosemide / spironolactone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: spironolactone 25mg/day, 16 weeks and furosemide 20mg/day, 16weeks
Trial: NCT00030264
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate will be given at a dose of 30mg/m2/week intramuscular (IM) or intravenous (IV) for the first 26 weeks, then every 2 weeks for the next 26 weeks or until disease progression (whichever occurs first)
Trial: NCT02191163
Drug: Antistax®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02191163
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02119273
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: See arm description
Trial: NCT00892580
Drug: STX209
FDA approved: no
EMA approved: no
PMDA approved: no
Description: collection of serum for DNA to elucidate a potential biomarker for patients with ASD
Trial: NCT00227110
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is given to match pioglitazone.
Trial: NCT01164826
Drug: Nabumetone
RxNorm normalized name: Nabumetone
DrugBank: Nabumetone (DB00461)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nabumetone 750 mg Tablets of Dr. Reddy's Laboratories Limited
Trial: NCT02232360
Drug: Rosuvastatin and fenofibrate
RxNorm normalized name: rosuvastatin and fenofibrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy: rosuvastatin 10 mg and fenofibrate 160 mg per day
Trial: NCT02232360
Drug: Rosuvastatin alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin 10mg per day
Trial: NCT02348021
Drug: Dual Anti Platelet Therapy
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients will receive Dual Anti Platelet Therapy for one month
Trial: NCT03984825
Drug: GSK3640254
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK3640254 will be available as a 100 mg capsule. Subjects will be administered 200 mg GSK3640254 once daily via the oral route on Days 11 to 21.
Trial: NCT00444314
Drug: Panzem® NCD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NCD suspension, 1500 mg TID daily for 6 week cycles
Trial: NCT01006733
Drug: Target INR 1.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: We will randomize patients to a target International Normalized Ratio (INR) of 2.5 or 1.8.
Trial: NCT03640884
Drug: Xueshuantong-Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xueshuantong-Injection is a kind of natural compound injection extracted from Chinese herb Notoginseng. The major bioactive ingredient is panax notoginseng saponins.
Trial: NCT01515371
Drug: Placebo Comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For three dose stages: solution prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), reconstitution volume 8 ml, 4 ml and 2.7 ml per vial, respectively. Injection volume is 0.4 ml for all three dose stages. Mode of administration: unilateral soft palate injection.
Trial: NCT01841996
Drug: ME1111 solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once a day for 28 days
Trial: NCT01841996
Drug: Vehicle Solution
RxNorm normalized name: compounding vehicle solution sugar free no. 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once a day for 28 days
Trial: NCT01943760
Drug: 0.9% saline
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03483948
Drug: HMPL-523
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HMPL-523 tablet
Trial: NCT03008187
Drug: SEL24/MEN1703
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SEL24/MEN1703 will be given as oral capsules once daily for 14 consecutive days over a 21-day treatment cycle.
Trial: NCT02441218
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablets to be taken orally twice daily, at 12-hours intervals, in the morning and in the evening during meals up to 42 months.
Trial: NCT00452829
Drug: Folic Acid and inositol
RxNorm normalized name: folic acid / inositol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Folic Acid and inositol
Trial: NCT00452829
Drug: Folic acid and placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Folic acid and placebo
Trial: NCT00739037
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00739037
Drug: PAZ-417
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00806585
Drug: Comparator: Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00806585
Drug: Comparator: HCTZ
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01959685
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, single dose
Trial: NCT00474903
Drug: acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT01103414
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, once daily for 84 days
Trial: NCT01170663
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramucirumab placebo IV infusion on Days 1 and 15 of every 4-week cycle
Trial: NCT01927913
Drug: SPD602
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 32, 50 or 75 mg/kg/day BID, capsule
Trial: NCT00427037
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: identical placebo pill orally by mouth
Trial: NCT03229538
Drug: Isotonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic saline pre-operative and intra-operative
Trial: NCT02621892
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02073474
Drug: Sativex®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contains delta-9-tetrahydrocannabinol (THC), 27 mg/mL; cannabidiol (CBD), 25 mg/mL; in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Each actuation delivers THC 2.7 mg and CBD 2.5 mg.
Trial: NCT03121521
Drug: Melatonin 10 mg
RxNorm normalized name: melatonin 10 MG
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: melatonin 10mg daily p.o.
Trial: NCT03121521
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 10mg daily p.o.
Trial: NCT01358162
Drug: SQ109
RxNorm normalized name: SQ109
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single oral dose of 300 mg of SQ109 given daily for 14 consecutive days.
Trial: NCT00060476
Drug: rofecoxib
RxNorm normalized name: Rofecoxib
DrugBank: Rofecoxib (DB00533)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00060476
Drug: Comparator: placebo (unspecified)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02045602
Drug: Abraxane®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125 mg/m2 intravenous administration
Trial: NCT00361712
Drug: Standard of care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural analgesia with parturients with cervical dilatation and painful labor (VAS \>5)
Trial: NCT01596270
Drug: SAR245409
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: tablet Route of administration: oral
Trial: NCT04581395
Drug: succinylcholine 1 minute after rocuronium pretreatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05 mg/kg up to 5 mg of rocuronium pretreatment followed by 1.0 mg/kg succinlycholine t = 1 min +/- 10 sec after pretreatment
Trial: NCT04581395
Drug: succinylcholine 2 minutes following rocuronium pretreatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05 mg/kg up to 5 mg of rocuronium pretreatment followed by 1.0 mg/kg succinlycholine t = 2 min +/- 10 sec after pretreatment.
Trial: NCT03083184
Drug: Ethanol
RxNorm normalized name: Ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: An ethanol 40 % v/v - enoxaparin 1000 U/mL (Ethenox) interdialytic lock solution
Trial: NCT04361279
Drug: SIBP-02
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection，100mg/10ml
Trial: NCT00679263
Drug: MN-221
RxNorm normalized name: Mn 2+
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial dose: 16 μg/min for 15 minutes followed by 8 μg/min for 105 minutes (2-hour infusion with a total dose of 1,080 μg)
Trial: NCT00679263
Drug: MN-221
RxNorm normalized name: Mn 2+
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subsequent dose: 30 μg/min for 15 minutes followed by 15 μg/min for 45 minutes (1-hr infusion with a total dose of 1,125 μg).
Trial: NCT00679263
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo intravenous infusion with dosing volume equivalent to active treatment.
Trial: NCT04544280
Drug: Xeomin Injectable Product
RxNorm normalized name: Xeomin Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection
Trial: NCT00185341
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01813084
Drug: RV1729 single dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Safety and tolerability of single escalating doses
Trial: NCT01813084
Drug: RV1729 matching placebo single dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Safety and tolerability of single escalating doses
Trial: NCT01813084
Drug: RV1729: 14 day repeat dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Safety and tolerability of repeat escalating doses
Trial: NCT01813084
Drug: RV1729 matching placebo: 14 day repeat dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Safety and tolerability of repeat escalating doses
Trial: NCT03279952
Drug: CNS Stimulant
RxNorm normalized name: CNS STIMULANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be stabilized by any FDA approved CNS stimulant medication during open label trial.
Trial: NCT03817580
Drug: Project X 26ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Application of antiseptic drug to the inguinal and abdomen areas of the subjects
Trial: NCT03817580
Drug: Project X 5.1ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Application of antiseptic drug to the inguinal and abdomen areas of the subjects
Trial: NCT00538850
Drug: Fentanyl sublingual spray
RxNorm normalized name: fentanyl Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the open-label titration period of the study, participants started at a dose of 100, 200, or 400 µg and titrated upward to a maximum dose of 1600 µg. Titration was stopped when the dose administered provided adequate analgesia for breakthrough pain without unacceptable side effects or the maximum titration period of 21±5 days was reached. In the double-blind period of the study, participants received fentanyl sublingual spray in doses of 100, 200, 400, 600, 800, 1200, or 1600 µg determined in the open-label titration period of the study.
Trial: NCT00538850
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo to fentanyl sublingual spray.
Trial: NCT02645799
Drug: LABR-312
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered intravenously at the time of percutaneous coronary intervention (PCI) with a drug eluting stent
Trial: NCT03849261
Drug: D635
RxNorm normalized name: FILTER,SUCTION DEVILBISS #7305D635
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference drug
Trial: NCT02106832
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo inhaled twice daily intermittently for 28 days on / 28 days off
Trial: NCT02106832
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo inhaled twice daily intermittently for 14 days on / 14 days off
Trial: NCT01416350
Drug: Azithromycin - 250 mg
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Part A - A single azithromycin dose of 250 mg.
Trial: NCT01416350
Drug: Azithromycin - 1000 mg
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Part A - A single azithromycin dose of 1000 mg.
Trial: NCT01416350
Drug: Azithromycin - 250 mg every other day for 3 weeks
RxNorm normalized name: azithromycin 250 MG
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Part B - Repeat dose study treating subjects with Azithromycin (250 mg every other day for 3 weeks), the dose approximates that used in the treatment of chronic neutrophil-related inflammatory conditions.
Trial: NCT01139151
Drug: 3 Day Thiarabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Starting dose 70 mg/m\^2 IV over 1 hour (±15 minutes) daily x 3
Trial: NCT01139151
Drug: 5 Day Thiarabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Starting dose 40 mg/m2 IV over 1 hour (±15 minutes) daily x 5
Trial: NCT04490681
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo group
Trial: NCT04342247
Drug: external testosteron
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: external testosteron
Trial: NCT02027792
Drug: Diclofenac Gel
RxNorm normalized name: diclofenac Topical Gel
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04106778
Drug: DMT310
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Powder
Trial: NCT04106778
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Topical Powder
Trial: NCT03290027
Drug: DFD-03
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DFD-03 Lotion
Trial: NCT00874601
Drug: Diovan® (valsartan)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The valsartan will be initially given 80 mg of Diovan® (valsartan) per oral once daily in the morning on day 1, and flexibly will be adjusted to a dose of 80 -320 mg per day during next 6 days if more than 30% of SBPs measured at least 4 times in a day will not get the target level of SBPs.~In those patients not achieving target level of blood pressure (more than 15% reduction of initial blood pressure or below 145 mmHg of systolic blood pressure), an additional antihypertensive drugs (diuretics, beta blockers) can be given despite of Valsartan 320 mg. If the BP is considered to be low enough, dose of valsartan can be decreased to 40 mg per day. If the administration of valsartan is judged to be inappropriate by duty doctor due to any reasons, it can be stopped and the reasons will be recorded.
Trial: NCT00963872
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 50 mg/kg intravenously (IV) over 2 hours on Day -6.
Trial: NCT01696643
Drug: CB-5945
RxNorm normalized name: BroveX CB
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01696643
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03791879
Drug: Caudal dexamedatomidine analgesia
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Technique performance (Caudal block): classical technique; palpation, identification and puncture with the patients in the lateral position (permits easy access to the airway under general anesthesia) using a 22-G short-beveled needle under sterile conditions advancing needle pierces the sacrococcygeal ligament.~After needle insertion, pre-calculated volume of Levob plus DEXM bolus was injected as follow; Group A Caudal Levob 0.125%+ DEXM 0.5µg/kg. Group B Caudal Levob 0.125%+ DEXM 1µg/kg. Group C Caudal Levob 0.125%+ DEXM 1. 5 µg/kg. Group D Caudal Levob 0.125%+ DEXM 2µg/kg.
Trial: NCT04165837
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part A - Single Ascending Dose matching placebo study Part B - Multiple Ascending Dose matching placebo study
Trial: NCT01374425
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Leucovorin 400 mg/m\^2 or dose deemed appropriate by Investigator via IV infusion over 2 hours will be administered every 2 weeks until disease progression or unacceptable toxicity.
Trial: NCT01374425
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 850 or 1000 mg/m\^2 may be offered in the event of unacceptable toxicity to oxaliplatin or irinotecan, to be given orally twice a day on Days 1 to 14 in 3-week cycles.
Trial: NCT00226356
Drug: Supplements of L-methionine, betaine and folate
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02551185
Drug: ACY-241
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01525043
Drug: Naproxen
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naproxen 500mg BID for the first 2 weeks
Trial: NCT02449187
Drug: JLP-1310, Fasted followed by fed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In period 1, the subjects will receive an oral pill of JLP-1310 under fasted condition.~In period 2, the subjects will receive an oral pill of JLP-1310 under fed condition.
Trial: NCT02449187
Drug: JLP-1310, Fed followed by fasted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In period 1, the subjects will receive an oral pill of JLP-1310 under fed condition.~In period 2, the subjects will receive an oral pill of JLP-1310 under fasted condition.
Trial: NCT01525043
Drug: Synera patch for 12hrs/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 synera patch to cover the treatment area applied for 12 hours, daily for the first 2 weeks